Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR

* The dose-escalation results of JSKN003 was reported at this AACR conference. * JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors. The ORR in patients with HER2+ BC was 100...

2024-04-10 08:40 1522

Neoss Integrate Australia 2024 - Integrate. Educate. Celebrate

QUEENSLAND, Australia, April 9, 2024 /PRNewswire/ -- This summer, Neoss Australia &New Zealand are celebrating 20 years of Intelligent Simplicity and invites the dental community to join us for an exceptional scientific program with over 21 speakers across two days. Taking place on the Gold Coas...

2024-04-09 23:24 1262

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held fromMarch 29th toApril 1st, 2024, in Shenzhen, China. The TICSSO was initiated by Prof. Xinghua Pan (Southern Medical University), Prof. Fuchou Tang (Peking Un...

2024-04-09 23:14 1390

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (...

2024-04-09 22:10 1088

Datasea Announces Intent of its CEO to Purchase Up $3,000,000 of its Common Stock in Open Market Purchases

BEIJING, April 9, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and Ch...

2024-04-09 22:00 3169

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-04-09 20:00 1153

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivat...

2024-04-09 19:59 856

GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at ...

2024-04-09 19:00 1324

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentatio...

2024-04-09 19:00 992

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center became the first in the nation to use a novel pulsed field ablation (PFA) system to treat patients with paroxysmal and persistent atrial fibrillation, a...

2024-04-09 18:15 1174

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

* Sales double in the USA, order intake increases by over 150 percent * More than 50 percent increase in order intake in EMEA * Business Area Technology & Services' sales grow by almost 25 percent * Further improvement in profitability * Exyte CEO Büchele: "Our follow-the-client strategy ...

2024-04-09 17:52 1403

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

News Summary: * New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi. * Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted anal...

2024-04-09 14:00 1293

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

PRINCETON, N.J. and SUZHOU, China, April 9, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilen...

2024-04-09 09:18 1316

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patient...

2024-04-09 08:30 1082

Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR

SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced thatthe positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb)combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or ...

2024-04-09 04:53 1366

MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the market...

2024-04-08 22:00 996

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

- Employing Lunit INSIGHT MMG, a Turkish study showcases 70% efficiency improvements, advancements in early cancer detection, and interval cancer detection in mammography SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cance...

2024-04-08 21:00 1283

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Medit Unveils i900: The Next Evolution of Intraoral Scanners

Secure a front-row seat for the debut of Medit i900 and discover the latest cutting-edge dental technology SEOUL, South Korea and LONG BEACH, Calif., April 8, 2024 /PRNewswire/ -- Medit (www.medit.com ), a leading provider of dental 3D scanners and digital dentistry solut...

2024-04-08 21:00 914

Medit Unveils i900: The Next Evolution of Intraoral Scanners

Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"

* Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision * Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Seegene Inc., a leading South Korean comp...

2024-04-08 20:00 1549

Seegene and UK Health Security Agency convene a summit to collectively realize

SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego

Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds in Retrospective and Prospective Settings Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict the Tissue of Origin of Ca...

2024-04-08 20:00 952

1 234 5 6 ... 575